NCT00001072View on ClinicalTrials.gov

A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers

PHASE1CompletedINTERVENTIONAL
Enrollment

140

Participants

Timeline

Start Date

Not specified

Study Completion Date

January 31, 1999

Conditions
HIV Infections
Interventions
BIOLOGICAL

ALVAC-HIV MN120TMGNP (vCP300)

BIOLOGICAL

ALVAC-RG Rabies Glycoprotein (vCP65)

BIOLOGICAL

rgp120/HIV-1 SF-2

Trial Locations (6)

14642

Univ. of Rochester AVEG, Rochester

35294

UAB AVEG, Birmingham

37232

Vanderbilt Univ. Hosp. AVEG, Nashville

63104

St. Louis Univ. School of Medicine AVEG, St Louis

98144

UW - Seattle AVEG, Seattle

Unknown

JHU AVEG, Baltimore

All Listed Sponsors
lead

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

NCT00001072 - A Phase I Safety and Immunogenicity Trial of Live Recombinant Canarypox ALVAC-HIV vCP300 and HIV-1 SF-2 rgp120 in HIV-1 Uninfected Adult Volunteers | Biotech Hunter | Biotech Hunter